Who is sponsoring NCT07024316?

NCT07024316 is sponsored by Atlas Molecular Pharma.

What drugs are being tested in NCT07024316?

Interventions in NCT07024316: ATL-001 (Ciclopirox oral solution).

What condition does NCT07024316 study?

NCT07024316 studies Congenital Erythropoietic Porphyria (CEP).

Is NCT07024316 still recruiting?

NCT07024316 is currently recruiting now. Last updated 24 March 2026.

Last reviewed 2026-03-24 · How we verify

NCT07024316: ATL001-PII-CEP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Investigate the Improvement of Photosensitivity in Terms of Skin Lesions Associated With CEP Following Administration of Oral ATL-001 (Ciclopirox Oral Solution) in Participants Aged >18 Years of Age With CEP

Recruiting now Phase 1, PHASE2 Last updated 24 March 2026

What this trial tests

Phase 1, PHASE2 trial testing ATL-001 (Ciclopirox oral solution) in Congenital Erythropoietic Porphyria (CEP) in 6 participants. Currently enrolling.

Timeline

29 January 2026

Primary endpoint
1 May 2028

1 June 2028

Quick facts

Lead sponsor	Atlas Molecular Pharma
Phase	Phase 1, PHASE2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	29 January 2026
Primary completion	1 May 2028
Estimated completion	1 June 2028
Sites	1 location across United States

Drugs / interventions tested

ATL-001 (Ciclopirox oral solution) — full drug profile →

Conditions studied

Congenital Erythropoietic Porphyria (CEP) — all drugs for Congenital Erythropoietic Porphyria (CEP) →

Sponsor

Atlas Molecular Pharma — full company profile →

Who can join

18 and older, any sex, with Congenital Erythropoietic Porphyria (CEP). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a study to investigate the effect of oral ATL-001 (ciclopirox) in CEP (Congenital Erythropoietic Porphyria) patients. During the study, it will be measured the improvement of skin lesions, fatigue and other clinical symptoms as well as blood parameters. Funding source - FDA OOPD

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Atlas Molecular Pharma trials

Trials by the same sponsor.

NCT05647343 — Study to Assess the Safety and Pharmacokinetics of ATL-001 (Ciclopirox Olamine) in Healthy Volunteers · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07024316 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Atlas Molecular Pharma
Last refreshed: 24 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07024316.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing